Digoxin toxicity

Digoxin toxicity is the dangerous effect of excessive Digoxin, a medicine used in intensive care to slow the heart’s firing mechanism. In the book, its significance grows from a pharmacological danger into a recurring forensic clue: patients suffer sudden, unexplained deterioration, and test results reveal a drug exposure their treatment records cannot account for. The cases expose how easily an ordinary hospital medication can become difficult to distinguish from routine care—and how much depends on recognizing the anomaly in time.

The drug and its first fatal case

Digoxin was a familiar presence in the intensive care unit, kept in small glass ampules in a drug closet and loaded into a plastic cassette. Nurses shortened its name in conversation and on charts. Charles Cullen calculated that three half-milligram ampules would make a dose of one and a half milligrams, which he considered potentially sufficient when injected into muscle. That calculation sets the clinical familiarity of the drug against the concealed violence of its use: the ampules and syringe belonged to an ordinary workplace, but the injection was not part of a patient’s authorized care.

On September 1, 1993, Cullen entered the room of Helen Dean, an elderly patient recovering from breast cancer surgery at Warren Hospital. Her son, Larry Dean, had stayed with her throughout her hospitalization. Cullen, dressed in white unlike the blue-uniformed nurses Larry had seen, ordered him out of the room. When Larry returned, Helen said she had been stuck; a small puncture mark on her inner thigh gave her account a visible detail. Her doctor initially suggested it might be a bug bite. By the next day she was sweating and violently ill. Her heart stopped, and resuscitation failed.

Larry pursued the discrepancy rather than accepting the death as routine. Helen’s oncologist confirmed that no injection had been scheduled, and nurses identified the male nurse she had described as Cullen. Larry called the Warren County Prosecutor’s Office and reported that he believed his mother had been murdered. Cullen was questioned by hospital staff and investigators, while a medical examiner sampled the tiny mark on Helen’s thigh. The examiner tested for nearly one hundred potentially lethal chemicals but did not test for Digoxin. Helen’s death was consequently classified as natural, leaving the suspected drug exposure without the test that might have confirmed it.

Easton Hospital and an unexplained blood level

A later episode at Easton Hospital centered on Ottomar Schramm, whose strokes had progressively limited his movement. His daughter, Kristina Toth, initially accepted the presence of a male nurse with a syringe, who said it was needed in case her father’s heart stopped. Schramm’s heart, however, was not the reason for his admission. The next day he looked markedly worse: his heart rate wavered and his blood pressure fell. He then appeared to stabilize, and his family began to hope he was recovering.

That hope changed when Schramm’s longtime physician, Dr. Robert Silberman, called Toth. Unauthorized blood tests had found Digoxin in Schramm’s blood, although he had never been prescribed the drug. The level was described as off the charts. A follow-up test confirmed the result, and Silberman told Toth to request an autopsy. Schramm died. When his family returned to the hospital, Cullen was still working the night shift. He asked whether they intended to request an autopsy, a question that unsettled Toth after Silberman’s warning. The episode made the unexplained presence of Digoxin—not simply a decline in a seriously ill patient—the central fact requiring investigation.

The Somerset cases: spikes without a treatment explanation

At Somerset Medical Center, the unexplained Digoxin cases became a cluster. On June 14, 2003, Cullen reviewed the chart of Jin Kyung Han, who had been admitted with Hodgkin’s lymphoma and heart disease. Her cardiologist had prescribed small doses of Digoxin, ordinarily maintaining a level around 0.63, but stopped the medication after deciding it might worsen her new arrhythmias. Cullen then used the Pyxis drug computer to call up Digoxin under an order for his own patient and cancel the order; the drawer opened anyway. He took two units and injected Digoxin into Han’s intravenous line, a dose eight times greater than any she had previously received.

Han became ill, vomited, and suffered a severe drop in heart rate. A blood test showed that her Digoxin level had risen from about 0.63 to 9.94. Her cardiologist ordered an antidote. Han remained seriously unwell but survived. The exact comparison between her ordinary level and the later result made the danger legible: this was not merely a vague deterioration but a dramatic increase in a drug that her doctor had specifically discontinued.

Reverend Florian Gall’s case sharpened the same contradiction. He had initially been critically ill, then improved; his do-not-resuscitate order was rescinded, and his Digoxin was discontinued. He began sitting up and eating, while his sister kept watch at his bedside. On June 28 he went into cardiac arrest and could not be revived. His bloodwork showed Digoxin levels far beyond the expected range. In the hospital’s internal accounting he became Patient 4, a designation that placed his death within a larger pattern rather than treating it as an isolated tragedy.

The numbers became especially difficult to explain when Assistant Pharmacist Nancy Doherty discussed the cases with Bruce Ruck. One patient had suffered Digoxin toxicity on June 16; another, Gall, on June 28, both on the same unit. Gall’s recorded levels had remained low before suddenly rising to 9.61 just after dawn on the twenty-eighth. Doherty confirmed that he had received no further Digoxin after physicians discontinued it. Ruck concluded that the increase could not have occurred without additional Digoxin. The timing and laboratory results transformed suspicion into a concrete problem: the drug level rose after treatment had stopped.

Recognition, reporting, and the investigative turn

Somerset first tried to account for the cases internally. Its administrators and pharmacy reviewed medication records and checked for recalls, drug interactions, equipment problems, and laboratory error; repeated tests confirmed the abnormal results. The hospital tightened controls on Digoxin, as it had on Insulin, and considered medication error and staff conduct among possible explanations. But on a recorded call, officials were also told that the pattern constituted a sentinel event—a threat to patient safety that needed to be reported. The New Jersey Department of Health and Senior Services was informed of four patient incidents, including the Digoxin cases involving Han and Gall.

For Amy Loughren, the connection between drug controls and patient harm was initially obscure. She objected to a new Insulin sign-out form because she considered its estimate of remaining medication inaccurate, and she demanded to know why Insulin was being handled like a narcotic. Although she had noticed frequent codes and many deaths, she did not suspect Cullen, whom she regarded as an exceptionally capable and helpful nurse. When investigators showed her a Pyxis printout from the night Gall died, she recognized Cullen’s activity. The record made it possible for her to imagine that her friend had done something terrible, though she could not easily reconcile that possibility with the person she thought she knew.

Loughren later weighed the risk of helping the detectives against her loyalty to Cullen, her job, and her employer. She feared that the investigators could be wrong or manipulating her, yet the paper record had changed what she could believe. She assisted the investigation and brought the detectives information about Cerner patient records, while continuing to feel exposed and isolated at work. The records and laboratory findings did not merely establish that Digoxin could poison patients; together, they helped make drug access, patient charts, and unexplained clinical events parts of the same inquiry.

Significance

Across Helen Dean, Ottomar Schramm, Jin Kyung Han, and Florian Gall, Digoxin toxicity appears in sharply different forms: a fatal injection site that was never tested for the drug, a startling level in a patient never prescribed it, an extreme rise after a physician stopped treatment, and a post-discontinuation spike followed by death. The cases resist explanation as ordinary decline because each contains a mismatch between the patient’s care and the amount of Digoxin found in the body. At the same time, the book shows how a clear laboratory anomaly does not automatically produce an immediate answer: testing can omit the relevant substance, institutional reviews can begin internally, and coworkers can struggle to accept what a medication record suggests.

The recurring blood levels are therefore both medical evidence and a narrative mechanism. They convert a hidden act into a measurable contradiction, prompting families, pharmacists, clinicians, and investigators to ask how the drug entered a patient’s system. Their force lies not in a single number alone, but in the pattern formed by that number, the treatment history, and the records of access. In that pattern, Digoxin toxicity becomes the thread linking bedside deaths to the larger investigation.